Other Industry Event, Other Industry Events, Virtual Events & Programming

Biotech SOTP Valuation – Wall Street Prep

February 24, 2021 | 10:00 AM - 6:00 PM

Share Event

Loading Events

Wait! A Note on Registration:

We’ve launched Cvent—our new events platform!

Registration for any event with a start date after Sept. 28 now requires a CFA Institute account.

I don’t have a CFA Institute account

  • No problem! You’ll have the chance to create one prior to registration.

I already have a CFA Institute account

  • Great! Be sure to use your existing credentials at registration.
Cvent Transition Guide

What You’ll Learn

Value a Pre-Revenue Biotech
Want to value a clinical-stage, pre-revenue biotech? An ordinary discounted cash flow analysis won’t cut it. Instead, you need to build a long-range sum-of-the-parts valuation.

This advanced virtual “Power Session” walks participants through the step-by-step process of valuing a biotech company

Taught by Experienced Professionals
This is NOT an academic exercise. It is taught by a healthcare-focused investment banking professional who understands how SOTP valuation is done on the job.

CFANY.org: $799.20
Standard Rate: $999


This virtual session goes from 9am-5pm EST


The boot camp focuses on the private equity deal process. Participants will learn about the PE roles and responsibilities throughout each phase of a deal, from the review of teasers and first round bids, to the due diligence process, the LOI phase, and progressing all the way to deal closing.

View Full Syllabus


This boot camp assumes proficiency in Excel. Enrollment includes access to our popular Excel Crash Course for those who need an Excel refresher.


Enrollment includes lifetime access to the following online course(s): Financial Statement Modeling, LBO Modeling

Additional Details

Who is this boot camp for?

This course is designed for professionals and those pursing a career in the following finance careers:

  • Investment Banking
  • Venture Capital
  • Private Equity
  • + Anyone who wants to learn how professionals build a biotech-sum-of-the-parts valuation

Boot Camp Details

This course is an intensive instructor-led training program where trainees learn how to value a clinical-stage, pre-revenue biotech by building a long-range sum-of-the-parts valuation. Ideal for investment banking, private equity and VC professionals focusing on the biotechnology industry, this seminar bridges the gap between academics and the real world and equips trainees with the practical modeling skill set needed to build a biotech SOTP valuation.

What You’ll Learn

  • Market size and revenue benchmarking for a therapeutic asset in clinical development.
  • Determine the appropriate launch curve to achieve full market penetration once a therapy is approved.
  • Apply the appropriate “probability of success” to a clinical-stage pre-revenue biotech company.
  • Apply key assumptions and tie together a long-range forecast of multiple products with a DCF analysis.
  • Build-up of operating expenses including a salesforce analysis for a “go-it-alone” marketing strategy.
  • Key learning objectives include
    • Overview of a sum of the parts valuation
    • Major building blocks for a biotech SOTP
    • Model assumptions dashboard
    • Biotech company lifecycle
    • Identify peak revenue opportunity
    • Therapeutic areas overview
    • Product launch timing and uptake curve
    • Patent life and loss of exclusivity
    • Road to commercialization
    • FDA clinical trials
    • Building a commercial infrastructure
    • Completing the SOTP
    • Probability of success
    • Finalizing the valuation model
    • Valuation sensitivities

This virtual training session is scheduled for 10a-6p (ET). The session will use interactive exercises as learners move back and forth between classroom lecture and small group breakout rooms.

Comprehensive training materials (manuals and online exercises), Detailed reusable modifiable Excel model templates, Unlimited e-mail support for content-related questions for 12 months post-seminar.